Several recent studies have highlighted possible advantages of buprenorphine maintenance treatment. A study by Montoya et al, 3 which evaluated buprenorphine treatment for concomitant cocaine and opiate dependence, was quite revealing. In it, 200 outpatients dependent on both substances were randomly assigned to double-blind groups receiving buprenorphine plus weekly individual drug abuse counselling. The study concluded that sublingual buprenorphine at 16 mg daily is well tolerated and effective in reducing concomitant opiate and cocaine use, and more important, the therapeutic effect on cocaine use appeared independent of that on opiate use. 3 An injectable depot formulation of buprenorphine that uses biodegradable polymer microcapsule technology has been developed. It is believed that this formulation would minimize the risks of patient nonadherence or illicit diversion of the medication. A study by Sigmon et al 4 looked at the effectiveness of this formulation. This was a double-blind, placebo-controlled study, and data collected from 2 studies involving a single injection of 58 mg of buprenorphine concluded that the depot formulation provided effective buprenorphine delivery over several weeks. 4 An earlier, open-label study by Sobel et al 5 had indicated that this depot formulation produced substantial opioid blockage that persisted for 6 weeks.
Thus studies show that buprenorphine would offer significant additional value in the course of time.
Adegboyega Oyemade, MD New Haven, Connecticut
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Illicit Opioid Use and Its Key Characteristics: A Select Overview and Evidence From a Canadian Multisite Cohort of Illicit Opioid Users
Dear Editor:
We are pleased to respond to Dr. Oyemade's queries of statements made in our article. First, regarding his questioning of our statement that "buprenorphine has been shown to be less or, at best, equally cost-effective when compared with methadone" 1 p 628 and the contrary evidence offered, 2 we propose that citing individual studies is not the preferable route to assess the evidence at hand. Instead, we refer to a recent authoritative review, which concluded that methadone maintenance treatment (MMT) "is more effective than . . . buprenorphine maintenance treatment" (BMT) for treatment retention, does "not differ from [BMT]" regarding heroin use during treatment, and was overall considered to be the "most effective [opioid maintenance treatment] in retaining patients in treatment and suppressing heroin use." 3, p 321-325 A further metaanalysis 4 found that subjects treated with buprenorphine had a higher "risk of discontinuing treatment" and "more positive urinalyses" than subjects receiving methadone and that "further research is needed to determine if [BMT] is more effective than methadone in particular settings or in particular subgroups of patients." 4, p 683 Another point to be considered here is that of cost-effectiveness, which also seems to favour MMT. 5 In summary, the available systematic reviews conclude that BMT has not demonstrated any additional effectiveness beyond that of MMT. This is also surprising insofar as major efforts from the pharmaceutical industry are underway promoting the establishment of BMT as the primary treatment option for opioid dependence. Concerning the second point raised by Dr Oyemade, namely, the benefits of MMT for nonopioid use, one also needs to exercise scientific caution and rigour to establish evidence-based claims. Although many studies have demonstrated reductions in cocaine or other stimulant use among MMT patients, the demonstration of these effects has typically focused on select patient subpopulations effectively retained in treatment (and not on studies based on intent-to-treat methodologies). 6 Given that ongoing stimulant use is often a factor of MMT program retention, these findings result in circular logic. In addition, several studies have shown that MMT patients may resort to increased cocaine or other stimulant use during MMT, likely to counter the undesirable (for example, numbing) side effects of methadone. 7-10 In short-apart from the fact, suggested in our article, that there is no clear biological or pharmacologic basis for a direct therapeutic effect of opioid maintenance treatment for nonopioid substance dependence-we currently do not see convincing or conclusive evidence for sustained and clear effects of stimulant use reduction among opioid users in MMT.
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